Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663093 | 0.87 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7671992 | 0.83 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7667388 | 0.82 | GABRG2 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7665241 | 0.82 | GABRG2 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12068741 | 0.73 | GABRA1 (0.64) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2461269 | 0.73 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7672131 | 0.72 | GABRG2 (0.68) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7665902 | 0.72 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19575097 | 0.72 | GABRG2 (0.67) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7671983 | 0.72 | GABRG2 (0.70) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6355638-B1 | COGNITION ACTIVATORS | MERCK SHARP & DOHME LTD. (GB) | 2002-03-12 | — | — | US | claimed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-11083732-B2 | Use of negative modulators of GABA receptors containing alpha5 subunits as fast acting antidepressants | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-10 | — | — | US | disclosed |
| US-10835513-B2 | Methods and treatments for the learning and memory deficits associated with Noonan syndrome | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3125902-B1 | USE OF NEGATIVE MODULATORS OF GABA RECEPTORS CONTAINING ALPHA5 SUBUNITS AS FAST ACTING ANTIDEPRESSANTS | UNIV MARYLAND (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-10206921-B2 | Methods and compositions for treating a subject for central nervous system (CNS) injury | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3388433-A1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotech Co., Ltd (CN) | 2018-10-17 | — | — | EP | disclosed |
| EP-3025716-B1 | SUBSTANCE FOR TREATMENT OR RELIEF OF PAIN | SHANGHAI INST BIOLOGICAL SCIENCES CAS (CN) | 2018-04-04 | — | — | EP | disclosed |
| US-20160158194-A1 | Methods and Treatments for the Learning and Memory Deficits Associated with Noonan Syndrome | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-09 | — | — | US | disclosed |
| EP-3025716-A1 | SUBSTANCE FOR TREATMENT OR RELIEF OF PAIN | Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-20150374705-A1 | Substances for treatment or relief of pain | Shanghai Institues for Biological Sciences (CN) | 2015-12-31 | — | — | US | disclosed |
| WO-2015153658-A2 | USE OF NEGATIVE MODULATORS OF GABA RECEPTORS CONTAINING ALPHA5 SUBUNITS AS FAST ACTING ANTIDEPRESSANTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-20120283323-A1 | Treating Learning Deficits with Inhibitors of HMG CoA Reductase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-08 | — | — | US | disclosed |
| US-8222293-B2 | Treating learning deficits with inhibitors of Hmg CoA reductase | Regents of the University of Carolina (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20070299096-A1 | Treating Learning Deficits With Inhibitors of Hmg CoA Reductase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-27 | — | — | US | disclosed |
| US-6355638-B1 | COGNITION ACTIVATORS | MERCK SHARP & DOHME LTD. (GB) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | GABRA5, CYP3A5, GABRA1 | GABRA1 3/4885GABRG2 23/4885GABRB3 21/4885 |
| US-20150374705-A1 | Substances for treatment or relief of pain | GABRB3, GABRB2, GABRB1 | GABRA1 7/4885GABRG2 16/4885GABRB3 1/4885 |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | GABRA5, CYP3A5, GABRA1 | GABRA1 3/4885GABRG2 23/4885GABRB3 21/4885 |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRA1 14/4885GABRG2 13/4885GABRB3 8/4885 |
| US-10206921-B2 | Methods and compositions for treating a subject for central nervous system (CNS) injury | GABBR2, GABBR1, GABRR3 | GABRA1 14/4885GABRG2 13/4885GABRB3 8/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRA1 16/4885GABRG2 13/4885GABRB3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.